{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:29:19Z","timestamp":1740137359135,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Suqian Key Laboratory of Hematology","award":["M202111"],"award-info":[{"award-number":["M202111"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221218"],"award-info":[{"award-number":["BK20221218"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Development Fund of Affiliated Hospital of Xuzhou Medical University","award":["XYFY2021001"],"award-info":[{"award-number":["XYFY2021001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01477-y","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:03:48Z","timestamp":1725462228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced platelet function through CAR-T cell therapy in relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"24","author":[{"given":"Ruixue","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuguang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5480-6577","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-Cell therapy in patients with relapsed or refractory multiple myeloma (cartitude-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"1477_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al. Anti-Bcma car T-cell therapy Bb2121 in relapsed or refractory multiple myeloma. New Engl J Med. 2019;380:12. https:\/\/doi.org\/10.1056\/NEJMoa1817226.","journal-title":"New Engl J Med"},{"key":"1477_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"1477_CR4","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1200\/jco.22.01824","volume":"41","author":"J Xia","year":"2023","unstructured":"Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41:2583\u201393. https:\/\/doi.org\/10.1200\/jco.22.01824.","journal-title":"J Clin Oncol"},{"key":"1477_CR5","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and Cd19 chimeric antigen receptor T Cells in multiple myeloma. J Clin Oncol. 2022;40:2246\u201356. https:\/\/doi.org\/10.1200\/JCO.21.01676.","journal-title":"J Clin Oncol"},{"key":"1477_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.04.075","author":"A Miller","year":"2024","unstructured":"Miller A, Daum R, Wang T, et al. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024. https:\/\/doi.org\/10.1016\/j.jcyt.2024.04.075.","journal-title":"Cytotherapy"},{"key":"1477_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","volume":"59","author":"M Mohan","year":"2024","unstructured":"Mohan M, Szabo A, Patwari A, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following Bcma directed chimeric antigen receptor T (Car T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59:647\u201352. https:\/\/doi.org\/10.1038\/s41409-024-02233-2.","journal-title":"Bone Marrow Transplant"},{"key":"1477_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/s41467-023-37699-z","volume":"14","author":"C Kuang","year":"2023","unstructured":"Kuang C, Xia M, An G, et al. Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in multiple myeloma. Nat Commun. 2023;14:2093. https:\/\/doi.org\/10.1038\/s41467-023-37699-z.","journal-title":"Nat Commun"},{"key":"1477_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.thromres.2023.05.016","volume":"227","author":"Z Li","year":"2023","unstructured":"Li Z, Que Y, Wang D, et al. Recovery-model: a model for car T-cell-related thrombocytopenia in relapsed\/refractory multiple myeloma. Thromb Res. 2023;227:62\u201370. https:\/\/doi.org\/10.1016\/j.thromres.2023.05.016.","journal-title":"Thromb Res"},{"key":"1477_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.26113","volume":"96","author":"SJ Nagle","year":"2021","unstructured":"Nagle SJ, Murphree C, Raess PW, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021;96:455\u201361. https:\/\/doi.org\/10.1002\/ajh.26113.","journal-title":"Am J Hematol"},{"key":"1477_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0049-3848(02)00003-8","volume":"105","author":"P Cieslar","year":"2002","unstructured":"Cieslar P, M\u00e1sov\u00e1 L, Scheiner T, et al. Oxidative stress and platelet function in multiple myeloma and renal insufficiency: clinical relations of different tests. Thromb Res. 2002;105:277\u201383. https:\/\/doi.org\/10.1016\/s0049-3848(02)00003-8.","journal-title":"Thromb Res"},{"key":"1477_CR12","doi-asserted-by":"publisher","first-page":"2264940","DOI":"10.1080\/09537104.2023.2264940","volume":"34","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Khan D, Rana RH, et al. Multiple myeloma and its treatment contribute to increased platelet reactivity. Platelets. 2023;34:2264940. https:\/\/doi.org\/10.1080\/09537104.2023.2264940.","journal-title":"Platelets"},{"key":"1477_CR13","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12032-012-0290-0","volume":"29","author":"M Robak","year":"2012","unstructured":"Robak M, Treli\u0144ski J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol. 2012;29:3574\u201380. https:\/\/doi.org\/10.1007\/s12032-012-0290-0.","journal-title":"Med Oncol"},{"key":"1477_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/cco.0000000000000237","volume":"27","author":"A Moscard\u00f3","year":"2015","unstructured":"Moscard\u00f3 A, Latorre A, Santos MT, Bonanad S, Vall\u00e9s J. Platelet function in malignant hematological disorders. Curr Opin Oncol. 2015;27:522\u201331. https:\/\/doi.org\/10.1097\/cco.0000000000000237.","journal-title":"Curr Opin Oncol"},{"key":"1477_CR15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/09537104.2018.1475636","volume":"29","author":"EJ Favaloro","year":"2018","unstructured":"Favaloro EJ, Bonar R. An update on quality control for the Pfa-100\/Pfa-200. Platelets. 2018;29:622\u20137. https:\/\/doi.org\/10.1080\/09537104.2018.1475636.","journal-title":"Platelets"},{"key":"1477_CR16","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"key":"1477_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, et al. Nccn guidelines\u00ae insights: multiple myeloma, version 3.2022. J Natl Compr Cancer Netw: JNCCN. 2022;20:8\u201319. https:\/\/doi.org\/10.6004\/jnccn.2022.0002.","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"1477_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"1477_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1477_CR20","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/01.Cir.0000141575.92958.9c","volume":"110","author":"M Frossard","year":"2004","unstructured":"Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392\u20137. https:\/\/doi.org\/10.1161\/01.Cir.0000141575.92958.9c.","journal-title":"Circulation"},{"key":"1477_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/jcla.21658","volume":"28","author":"I Djunic","year":"2014","unstructured":"Djunic I, Elezovic I, Ilic V, et al. The effect of paraprotein on platelet aggregation. J Clin Lab Anal. 2014;28:141\u20136. https:\/\/doi.org\/10.1002\/jcla.21658.","journal-title":"J Clin Lab Anal"},{"key":"1477_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020480","author":"V Gkalea","year":"2023","unstructured":"Gkalea V, Fotiou D, Dimopoulos MA, Kastritis E. Monoclonal gammopathy of thrombotic significance. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15020480.","journal-title":"Cancers (Basel)"},{"key":"1477_CR23","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.jtha.2023.08.014","volume":"21","author":"AS Wolberg","year":"2023","unstructured":"Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost: JTH. 2023;21:3005\u201315. https:\/\/doi.org\/10.1016\/j.jtha.2023.08.014.","journal-title":"J Thromb Haemost: JTH"},{"key":"1477_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020;26:865\u201375. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.027.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1477_CR25","doi-asserted-by":"publisher","first-page":"9060143","DOI":"10.1155\/2016\/9060143","volume":"2016","author":"SH Yun","year":"2016","unstructured":"Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int. 2016;2016:9060143. https:\/\/doi.org\/10.1155\/2016\/9060143.","journal-title":"Biomed Res Int"},{"key":"1477_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1182\/blood.V73.1.172.172","volume":"73","author":"JA Ware","year":"1989","unstructured":"Ware JA, Clark BA, Smith M, Salzman EW. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood. 1989;73:172\u20136.","journal-title":"Blood"},{"key":"1477_CR27","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, et al. Modified easix predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5:3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"key":"1477_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-021-01101-6","volume":"14","author":"M Ke","year":"2021","unstructured":"Ke M, Kang L, Wang L, et al. Car-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. J Hematol Oncol. 2021;14:90. https:\/\/doi.org\/10.1186\/s13045-021-01101-6.","journal-title":"J Hematol Oncol"},{"key":"1477_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in car T-cell toxicity: mechanisms. Manif Manag Blood Rev. 2019;34:45\u201355. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002.","journal-title":"Manif Manag Blood Rev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01477-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01477-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01477-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:28:13Z","timestamp":1732987693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01477-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01477-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the human studies review board at the Affiliated Hospital of Xuzhou Medical University (ClinicalTrials.gov # NCT02782351). All patients provided written informed consent before received CAR-T cell therapy. The clinical investigation was conducted according to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"210"}}